by GOAI
由GOAI生成
Share To
分享到
Nuvation Bio has initiated a pivotal global Phase 3 clinical trial, known as the SIGMA Trial (G203), to evaluate the efficacy and safety of safusidenib in patients with IDH1-mutant glioma. The announcement marks a significant step in the development of safusidenib, an investigational therapy targeting isocitrate dehydrogenase 1 (IDH1) mutations, which are commonly associated with certain types of gliomas.
Nuvation Bio 已啓動了一項關鍵的全球 III 期臨牀試驗，稱為 SIGMA 試驗（G203），以評估 safusidenib 在 IDH1 突變型膠質瘤患者中的療效和安全性。這一宣佈標誌着 safusidenib 開發邁出了重要一步，safusidenib 是一種針對異檸檬酸脫氫酶 1（IDH1）突變的在研療法，該突變常與某些類型的膠質瘤相關。
The trial aims to assess whether safusidenib can provide therapeutic benefits for patients with this specific genetic mutation..
該試驗旨在評估沙福西尼是否可以為具有這種特定基因突變的患者提供治療益處。
The SIGMA Trial will enroll participants globally and focus on individuals diagnosed with IDH1-mutant glioma. Safusidenib is designed to inhibit mutant IDH1 enzymes, which play a role in tumor growth by altering cellular metabolism. The study will measure key outcomes such as progression-free survival and overall survival rates among participants receiving safusidenib compared to those receiving standard treatment options.
SIGMA 試驗將在全球範圍內招募參與者，並專注於確診為 IDH1 突變型膠質瘤的個體。Safusidenib 旨在抑制突變的 IDH1 酶，這種酶通過改變細胞代謝在腫瘤生長中發揮作用。該研究將衡量接受 Safusidenib 的參與者與接受標準治療的參與者之間的關鍵結果，如無進展生存期和總生存率。
This Phase 3 trial follows earlier studies that evaluated the drug’s potential effectiveness and safety profile in treating IDH1-mutant cancers. Further details regarding enrollment criteria, locations, and timelines have not yet been disclosed..
這項 III 期試驗是在早期研究之後進行的，早期研究評估了該藥物在治療 IDH1 突變癌症中的潛在有效性和安全性。關於入組標準、地點和時間表的更多細節尚未披露。
Newsflash | Powered by GeneOnline AI
新聞快訊 | 由GeneOnline AI提供支持
Source: GO-AI-ne1
來源：GO-AI-ne1
For any suggestion and feedback, please contact us.
如有任何建議和反饋，請聯繫我們。
Date: February 9, 2026
日期：2026年2月9日
©www.geneonline.com All rights reserved. Collaborate with us:
©www.geneonline.com 版權所有。與我們合作：
[email protected]
電子郵件地址
Author
作者
GOAI
GOAI
Related Post
相關文章